Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have received a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $43.1429.

ZBIO has been the subject of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a research report on Tuesday, January 6th. Evercore began coverage on Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price target for the company. HC Wainwright restated a “buy” rating and set a $44.00 price objective on shares of Zenas BioPharma in a report on Tuesday, February 10th. Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Finally, Wall Street Zen upgraded Zenas BioPharma from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st.

Insider Transactions at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. bought 57,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average cost of $17.96 per share, with a total value of $1,023,720.00. Following the completion of the transaction, the chief executive officer owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. The trade was a 15.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Hongbo Lu purchased 25,985 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were bought at an average cost of $22.50 per share, with a total value of $584,662.50. Following the transaction, the director directly owned 347,968 shares of the company’s stock, valued at $7,829,280. The trade was a 8.07% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 202,845 shares of company stock worth $3,747,185 in the last three months. Company insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Polar Capital Holdings Plc acquired a new stake in Zenas BioPharma during the fourth quarter worth about $38,402,000. Federated Hermes Inc. increased its position in Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after purchasing an additional 853,740 shares in the last quarter. EcoR1 Capital LLC purchased a new position in Zenas BioPharma in the fourth quarter valued at approximately $28,667,000. NEA Management Company LLC lifted its position in Zenas BioPharma by 28.9% during the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after buying an additional 789,500 shares in the last quarter. Finally, NEXTBio Capital Management LP purchased a new stake in Zenas BioPharma during the fourth quarter worth approximately $11,691,000.

Zenas BioPharma Trading Down 0.0%

Shares of ZBIO stock opened at $26.35 on Friday. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -3.73 and a beta of -1.50. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37. The firm has a 50-day moving average price of $25.35 and a 200 day moving average price of $26.40. Zenas BioPharma has a twelve month low of $6.11 and a twelve month high of $44.60.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.